abstract |
The present disclosure relates to new sulfonylurea compounds and related compounds useful in the treatment of a disorder sensitive to the modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process. |